SMAD7 and diabetic kidney disease: There was a decreased expression of Smad7 in the experimental group compared with the NC group, particularly evident in the diabetic nephropathy group (P < 0.01), but Smad7 expression increased following MG132 treatment, and the increase in the MH group was more pronounced than in the ML group (P < 0.05).